Our previous study found that promyelocytic leukemia (PML)/retinoic acid receptor-alpha (RARα) can maintain the nuclear expression levels of NRF2 by inhibiting the degradation rate of the NRF2 protein, and inhibition of the NRF2 signaling pathway makes acute promyelocytic leukemia (APL) cells more sensitive to arsenic trioxide (ATO) and Ara-C [26]. This evidence concerns the gene RARA and leukemia.